Market Newsdesk

February 24, 2026 4:06 pm

Backblaze Appoints Rhett Dillingham Senior Vice President of Product

Backblaze Appoints Rhett Dillingham Senior Vice President of Product

Backblaze adds strategic AI and cybersecurity leader to drive innovation and operational excellence to continue scaling its platform for the AI era

SAN MATEO, Calif.–(BUSINESS WIRE)–
Backblaze, Inc. (Nasdaq: BLZE), the high-performance cloud storage platform for the AI era, today announced the appointment of Rhett Dillingham as Senior Vice President of Product, strengthening the company’s executive leadership team as its cloud storage platform and AI use cases continue to scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224045978/en/

Rhett Dillingham, Senior Vice President of Product at Backblaze

Dillingham brings more than two decades of product management and design leadership experience building high growth, globally developed and delivered cloud platforms. In his role, he oversees Backblaze’s product organization driving customer-centric product innovation to support the growing demands of AI and data-intensive workloads.

“Rhett’s experience leading product teams across AI, cloud infrastructure, and cybersecurity make him an excellent leader for our product organization,” said Gleb Budman, co-founder and CEO of Backblaze. “As customers rely on Backblaze to power AI-driven and mission-critical workloads, his background building global platforms will help us innovate faster and strengthen our storage cloud for the next generation of applications.”

Prior to joining Backblaze, Dillingham served as Senior Vice President of Product at HackerOne, where he led the company’s product management and design functions in AI-powered platform development for continuous threat exposure reduction. Prior to that, he was Vice President of Product at Sumo Logic and Rackspace after holding product leadership roles at AWS, Microsoft, and AMD.

“Backblaze’s differentiated combination of cloud storage performance with cost predictability empowers application builders to focus on innovation instead of cost to ship bolder application capabilities faster,” said Dillingham. “This is especially applicable in the burgeoning AI-powered application development space, and I am thrilled to join the team in advancing Backblaze’s platform capabilities addressing these growing customer object storage needs.”

Dillingham comes to Backblaze having built and led product teams responsible for some of the industry’s highest scale global cloud and cybersecurity platforms. In this new role, he will guide the customer-centric build-out of the company’s storage cloud as it supports the next generation of AI-powered and data-driven applications.

About Backblaze

Backblaze (NASDAQ: BLZE) gives businesses the freedom to innovate without limits by removing the barriers of lock-in, complexity, and cost. Our high-performance cloud object storage accelerates AI workflows, powers data-heavy applications, streamlines media management, and protects critical data. As an award-winning independent cloud, we provide unparalleled levels of interoperability that enable over 500,000 of our customers to reach and serve hundreds of millions of end users in 175 countries around the world. For more information, please go to www.backblaze.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224045978/en/

Press Contact:

Yev Pusin

Head of Communications

[email protected]

KEYWORDS: California United States North America Canada

INDUSTRY KEYWORDS: Security Data Management Technology Artificial Intelligence Software

MEDIA:

Photo

Rhett Dillingham, Senior Vice President of Product at Backblaze

Logo

February 24, 2026 4:05 pm

Micron Technology to Report Fiscal Second Quarter Results on March 18, 2026

BOISE, Idaho, Feb. 24, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) announced today that it will hold its fiscal second quarter earnings conference call on Wednesday, Mar. 18, 2026, at 2:30 p.m. Mountain time.

The call will be webcast live at http://investors.micron.com/. Webcast replays of presentations can be accessed from Micron’s Investor Relations website for approximately one year after the call.

About Micron Technology, Inc.
Micron Technology, Inc. is an industry leader in innovative memory and storage solutions transforming how the world uses information to enrich life for all. With a relentless focus on our customers, technology leadership, and manufacturing and operational excellence, Micron delivers a rich portfolio of high-performance DRAM, NAND, and NOR memory and storage products. Every day, the innovations that our people create fuel the data economy, enabling advances in artificial intelligence (AI) and compute-intensive applications that unleash opportunities — from the data center to the intelligent edge and across the client and mobile user experience. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.

© 2026 Micron Technology, Inc. All rights reserved. Information, products, and/or specifications are subject to change without notice. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners.

Micron Media Relations Contact

Mark Plungy
Micron Technology, Inc.
+1 (408) 203-2910
[email protected]

Micron Investor Relations Contact
Satya Kumar
Micron Technology, Inc.
+1 (408) 450-6199
[email protected]

February 24, 2026 4:05 pm

Tempus Reports Fourth Quarter and Full Year 2025 Results

Tempus Reports Fourth Quarter and Full Year 2025 Results

CHICAGO–(BUSINESS WIRE)–
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025.

Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry)

Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hereditary volume growth of 23%

MRD volume was ~4,700 tests in the fourth quarter, up 56% quarter-over-quarter

Data and Applications revenue of $100.4 million in the fourth quarter, representing 25.1% year-over-year growth, with Insights (data licensing) growing 69.5%, excluding the impact of the AstraZeneca warrant in Q4 of 2024

Ended the year with over $1.1 billion in Total Remaining Contract Value and 126% Net Revenue Retention

$759.7 million in cash and marketable securities as of December 31, 2025

Revenue guidance of $1.59 billion for 2026 and expect full year 2026 Adjusted EBITDA of approximately $65 million

“In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space,” said Eric Lefkofsky, Founder and CEO of Tempus. “The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world.”

Fourth Quarter Summary Results:

Revenue increased 83.0% year-over-year to $367.2 million in the fourth quarter.

Diagnostics generated $266.9 million of revenue in the quarter, representing 121.6% year-over-year growth, with Oncology volume growth of 29% year-over-year and Hereditary volume growth of 23%.

Data and Applications generated $100.4 million of revenue in the quarter, representing 25.1% year-over-year growth, with Insights growing 69.5% (excluding the impact of the AstraZeneca warrant in Q4 of 2024).

Gross profit increased 94.7% year-over-year to $237.7 million, led by strong performance in Diagnostics.

Net loss was ($54.2 million), which included $48.7 million of stock compensation expense and related employer payroll taxes in the fourth quarter, compared to a net loss of ($13.0 million) in the fourth quarter of 2024 and a net loss of ($80.0 million) in the third quarter of 2025.

Adjusted EBITDA improved to $12.9 million in the fourth quarter, compared to ($7.8 million) in the fourth quarter of 2024 and $1.5 million in the third quarter of 2025.

Full Year 2025 Summary Results:

Revenue increased 83.4% year-over-year to $1.3 billion in 2025.

Diagnostics generated $955.4 million of revenue, or 111.5% year-over-year growth, with Oncology volume growth of 26% year-over-year and Hereditary volume growth of 29%.

Data and Applications generated $316.4 million of revenue, accelerating 30.9% year-over-year, with Insights growth of 38.0%.

Ended the year with over $1.1 billion in remaining Total Contract Value and Net Revenue Retention of 126%.

Gross profit increased to $797.9 million, representing 109.4% growth year-over-year.

Net loss was ($245.0 million), which included $136.3 million of stock compensation expense and related employer payroll taxes.

Adjusted EBITDA improved $97.3 million year-over-year to ($7.4 million), even after the acquisitions of Paige AI and OneOme.

Recent Operational Highlights

Launched Paige Predict, an AI-powered digital pathology suite that analyzes standard H&E slides to predict 123 biomarkers across 16 cancer types, helping clinicians make informed testing decisions even when tissue samples are limited, which improves Tempus’ ability to render insights across its genomic tests.

Announced results from a new study demonstrating that Tempus’ AI-driven Immune Profile Score (IPS) test more accurately predicts immunotherapy outcomes across various cancers than conventional biomarkers, identifying potential responders—including 13% of colorectal and 17% of rare cancer patients—who would otherwise be overlooked by standard testing.

Entered a multi-year strategic collaboration with NYU Langone Health, centered on a prospective observational study that uses serial molecular profiling to track cancer evolution and treatment resistance, with the goal of developing AI-powered diagnostic tools and personalized therapies.

Selected by Northwestern Medicine to expand genomic testing access to oncology patients across the health system, leveraging Tempus’ full suite of DNA, RNA, liquid biopsy, and MRD tests to enable more personalized cancer care and clinical trial design.

Fourth Quarter and Full Year 2025 Financial Results

	Three Months Ended December 31, 2025			Year Ended December 31, 2025
	(in thousands, except percentages and per share amounts)
	(unaudited)
Revenue	$	367,211		$	1,271,789
Year-over-year growth		83.0	%		83.4	%
Gross profit	$	237,713		$	797,897
Loss from operations	$	(61,413	)	$	(252,872	)
Net loss	$	(54,166	)	$	(245,028	)
Adjusted EBITDA	$	12,893		$	(7,385	)
Net loss per share attributable to common shareholders, basic and diluted	$	(0.30	)	$	(1.41	)
Non-GAAP net loss per share	$	(0.04	)	$	(0.61	)

Financial Outlook and Guidance

Tempus is providing full year 2026 revenue guidance of approximately $1.59 billion, which represents ~25% annual growth. We expect 2026 Adjusted EBITDA to be ~$65 million.

For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.

Webcast and Conference Call Information

A conference call and webcast will begin today, February 24, 2026 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:

Conference ID: 4652845

United States – New York: (646) 307-1963

USA & Canada – Toll-Free: (800) 715-9871

Live webcast: https://edge.media-server.com/mmc/p/c83akphq/

The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Non-GAAP Financial Measures

In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.

Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”). Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue. Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to our IPO. Non-GAAP loss from operations is defined as loss from operations, adjusted to exclude (i) stock-based compensation expense, (ii) employer payroll tax related to stock-based compensation expense, (iii) acquisition-related expenses, (iv) franchise taxes related to our IPO, and (v) amortization of intangibles due to acquisition. Non-GAAP net loss is defined as net loss, adjusted to exclude (i) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (ii) stock-based compensation expense, (iii) employer payroll tax related to stock-based compensation expense, (iv) acquisition-related expenses, (v) amortization of intangibles due to acquisition, (vi) losses from equity method investments, (vii) (benefit from) provision for income taxes, (viii) the payment of $2.3 million of our Series G-4 convertible preferred stock in connection with the initial public offering (the “G-4 Special Payment”), (ix) franchise taxes related to our IPO, (x) other tax expense, (xi) loss on debt extinguishment, and (xii) amortization of deferred other income from our IP License Agreement with SB Tempus. Non-GAAP net loss per share is defined as non-GAAP net loss divided by weighted average common shares outstanding, basic and diluted.

Adjusted EBITDA is defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) (benefit from) provision for income taxes, (v) losses from equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) stock-based compensation expense, (viii) employer payroll tax related to stock-based compensation expense, (ix) acquisition-related expenses, (x) the G-4 Special Payment, (xi) amortization of deferred other income from our IP License Agreement with SB Tempus, (xii) franchise taxes related to our IPO, (xiii) other tax expense and (xiv) loss on debt extinguishment.

Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.

Other Key Metrics

Total Remaining Contract Value (TCV) is equal to the total potential value of signed contracts and assumes the exercise of all contract options, all discretionary opt-ins, and no early termination. Remaining TCV excludes any revenue recognized to date on these contracts or any future adjustments made to the contractual value as a result of amendments or terminations.

Net Revenue Retention compares the annual Insights product revenue generated from all customers that made an Insights purchase in one year to the annual Insights product revenue generated from the same cohort of customers in the subsequent year.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for 2026; and Tempus ability to drive significant growth over the next several years and enhance the lives of millions of patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics and Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“the SEC”) on February 24, 2026. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Tempus AI, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share amounts)

	Year Ended December 31,
	2025			2024			2023
Net revenue
Diagnostics	$	955,381		$	451,749		$	363,022
Data and applications⁽¹⁾		316,408			241,649			168,800
Total net revenue	$	1,271,789		$	693,398		$	531,822
Cost and operating expenses
Cost of revenues, diagnostics		386,102			243,467			189,165
Cost of revenues, data and applications		87,790			68,818			56,482
Technology research and development		146,107			167,519			95,155
Research and development		172,924			149,325			90,343
Selling, general and administrative		731,738			755,351			296,760
Total cost and operating expenses		1,524,661			1,384,480			727,905
Loss from operations	$	(252,872	)	$	(691,082	)	$	(196,083	)
Interest income		12,628			11,084			7,601
Interest expense		(70,267	)		(53,653	)		(46,869	)
Loss on debt extinguishment		(12,034	)		—			—
Other income, net		31,447			32,336			21,822
Loss before benefit from (provision for) income taxes	$	(291,098	)	$	(701,315	)	$	(213,529	)
Benefit from (provision for) income taxes		51,684			(266	)		(288	)
Losses from equity method investments		(5,614	)		(4,228	)		(301	)
Net Loss	$	(245,028	)	$	(705,809	)	$	(214,118	)
Accretion of convertible preferred stock to redemption value		—			—			(4,338	)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares		—			(39,347	)		(44,497	)
Cumulative undeclared dividends on Series C preferred shares		—			(1,174	)		(3,011	)
Net loss attributable to common shareholders, basic and diluted		(245,028	)		(746,330	)		(265,964	)
Net loss per share attributable to common shareholders, basic and diluted	$	(1.41	)	$	(6.23	)	$	(4.20	)
Weighted-average shares outstanding used to compute net loss per share, basic and diluted		174,264			119,849			63,306
Comprehensive Loss, net of tax
Net loss	$	(245,028	)	$	(705,809	)	$	(214,118	)
Foreign currency translation adjustment		808			89			(13	)
Comprehensive loss	$	(244,220	)	$	(705,720	)	$	(214,131	)

⁽¹⁾	Includes related party revenue of $65,251, $4,502 and $673 for the years ended December 31, 2025, 2024 and 2023, respectively.

Tempus AI, Inc. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)

	December 31, 2025		December 31, 2024
Assets
Current Assets
Cash and cash equivalents	$	604,787	$	340,954
Accounts receivable⁽¹⁾, net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively		311,170		154,819
Inventory		51,724		38,386
Related party asset		8,785		—
Prepaid expenses and other current assets		40,498		26,135
Marketable equity securities		150,211		107,309
Total current assets	$	1,167,175	$	667,603
Property and equipment, net		89,156		58,056
Goodwill		470,211		73,343
Intangible assets, net		355,253		11,716
Investments and other assets		21,111		8,305
Investment in joint venture		86,557		91,450
Related party asset, less current portion		16,215		—
Operating lease right-of-use assets		64,496		14,762
Restricted cash		4,664		881
Total Assets	$	2,274,838	$	926,116

Liabilities, Convertible redeemable preferred stock, and Stockholders’ equity
Current Liabilities
Accounts payable		81,994		53,804
Accrued expenses		155,370		130,407
Deferred revenue⁽²⁾		92,673		75,981
Deferred other income		15,955		15,955
Other current liabilities		8,680		6,964
Operating lease liabilities		13,355		6,459
Accrued data licensing fees		4,361		1,500
Total current liabilities	$	372,388	$	291,070
Operating lease liabilities, less current portion		74,272		26,199
Convertible promissory note		208,672		168,192
Other long-term liabilities		56,600		15,980
Revolving credit facility		100,000		—
Interest payable		12,393		70,450
Long-term debt, net		202,753		267,244
Convertible senior notes, net		728,078		—
Deferred other income, less current portion		7,977		23,932
Deferred revenue, less current portion		20,379		6,710
Total Liabilities	$	1,783,512	$	869,777

⁽¹⁾	Includes related party accounts receivable of $6,428 and $4,287 as of December 31, 2025 and 2024, respectively.
⁽²⁾	Includes related party deferred revenue of $3,938 and $0 as of December 31, 2025 and 2024, respectively.

Tempus AI, Inc. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)

Commitments and contingencies (Note 7)
Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024	$	—		$	—
Stockholders’ equity
Class A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at December 31, 2025 and 2024, respectively; 173,235,428 and 157,076,972 shares issued and outstanding at December 31, 2025 and 2024, respectively		17			16
Class B Common Stock, $0.0001 par value, 5,500,000 shares authorized at December 31, 2025 and 2024, respectively; 5,043,789 issued and outstanding at December 31, 2025 and 2024, respectively		1			1
Non-voting Common Stock, $0.0001 par value, no shares authorized at December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025, and 2024, respectively		—			—
Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost		(6,642	)		(3,602	)
Additional Paid-In Capital		2,892,910			2,210,664
Accumulated Other Comprehensive Income		902			94
Accumulated deficit		(2,395,862	)		(2,150,834	)
Total Stockholders’ equity	$	491,326		$	56,339
Total Liabilities, Convertible redeemable preferred stock, and Stockholders’ equity	$	2,274,838		$	926,116

Tempus AI, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, except per share amounts)

	Year Ended December 31,
	2025			2024			2023
Operating activities
Net loss	$	(245,028	)	$	(705,809	)	$	(214,118	)
Adjustments to reconcile net loss to net cash used in operating activities
Change in fair value of warrant liability		—			42,400			(8,000	)
Gain on warrant termination		—			(39,100	)		—
Reversal of warrant contract asset amortization		—			(16,301	)		—
Stock-based compensation		124,747			534,138			—
Gain on warrant exercise		—			(173	)		—
Gain on marketable equity securities		(16,471	)		(12,110	)		(9,807	)
Loss on disposal of property and equipment		415			—			—
Loss on debt extinguishment		12,034			—			—
Deferred income taxes		(52,665	)		—			—
Losses from equity method investments		5,614			4,228			301
Amortization of original issue discount		4,088			1,382			1,117
Amortization of deferred financing fees		484			510			510
Change in fair value of contingent consideration		—			72			(400	)
Change in fair value of holdback liability		(1,337	)		—			—
Amortization of warrant contract asset		—			4,843			5,221
Depreciation and amortization		102,324			37,245			33,049
Provision for bad debt expense		2,558			680			1,646
Provision for obsolete inventory		1,335			—			—
Amortization of finance right-of-use lease assets		—			—			283
Change in fair value of warrant asset		—			(18,302	)		(4,100	)
Non-cash operating lease costs		11,554			6,047			6,760
Minimum accretion expense		268			197			90
Impairment of intangible assets		—			—			7,359
PIK interest added to principal		10,537			8,811			3,587
Change in assets and liabilities
Accounts receivable⁽¹⁾		(90,402	)		(61,037	)		(7,347	)
Inventory		(3,369	)		(9,541	)		(6,563	)
Prepaid expenses and other current assets		(1,699	)		(13,683	)		(6,474	)
Investments and other assets		(17,301	)		(751	)		(4,209	)
Accounts payable		(7,241	)		(23,852	)		(23,363	)
Related party asset		(25,000	)		—			—
Deferred revenue⁽²⁾		(6,960	)		(20,942	)		(26,412	)
Deferred other income		(15,955	)		39,887			—
Accrued data licensing fees		2,966			(5,000	)		(9,121	)
Accrued expenses & other		(12,844	)		50,540			38,577
Interest payable		14,206			15,129			15,836
Operating lease liabilities		(14,948	)		(8,553	)		(8,761	)
Net cash used in operating activities	$	(218,090	)	$	(189,045	)	$	(214,339	)

⁽¹⁾	Includes increase in related party accounts receivable of $2,141 and $4,203 as of December 31, 2025 and 2024, respectively. Includes decrease in related party accounts receivable of $318 as of December 31, 2023.

⁽²⁾	Includes increase in related party deferred revenue of $3,938 , $0 and $0 as of December 31, 2025, 2024 and 2023, respectively.

Tempus AI, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, except per share amounts)

	Year Ended December 31,
	2025			2024			2023
Investing activities
Purchases of property and equipment	$	(21,049	)	$	(22,121	)	$	(34,608	)
Proceeds from sale of marketable equity securities		8,316			23,098			—
Purchases of marketable equity securities		(2,740	)		(36,183	)		—
Business combinations, net of cash acquired (Note 3)		(376,666	)		—			(5,705	)
Investment in joint venture		—			(95,186	)		—
Capitalized software costs		(6,216	)		—			—
Net cash used in investing activities	$	(398,355	)	$	(130,392	)	$	(40,313	)

Financing activities
Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions	$	—		$	381,951		$	—
Tax withholding related to net share settlement of restricted stock units		—			(69,918	)		—
Issuance of Series G-4 Preferred Stock, net of offering costs		—			—			44,885
Issuance of Series G-5 Preferred Stock		—			199,750			—
Principal payments on finance lease liabilities		—			—			(288	)
Purchase of treasury stock		(3,040	)		—			(3,602	)
Payment of deferred offering costs		(806	)		(8,766	)		(698	)
Dividends paid		—			(5,625	)		(5,625	)
Proceeds from revolving credit facility, net of original issue discount		98,000			—			—
Proceeds from long-term debt, net of original issue discount		196,000			—			82,875
Proceeds from convertible senior notes, net of initial purchasers’ discount		726,497			—			—
Payment of deferred financing fees		(1,519	)		—			—
Payment of indemnity holdback related to acquisition		—			(813	)		—
G-4 Special Payment		—			(2,250	)		—
Principal payments on long-term debt		(276,892	)		—			—
Prepayment premium on long-term debt		(7,841	)		—			—
Purchases of capped call		(41,775	)		—			—
Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions		195,499			—			—
Net cash provided by financing activities	$	884,123		$	494,329		$	117,547
Effect of foreign exchange rates on cash	$	(62	)	$	336		$	(19	)

Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash	$	267,616		$	175,228		$	(137,124	)
Cash, cash equivalents and restricted cash, beginning of period		341,835			166,607			303,731
Cash, cash equivalents and restricted cash, end of period	$	609,451		$	341,835		$	166,607

Cash, Cash Equivalents and Restricted Cash are Comprised of:
Cash and cash equivalents	$	604,787		$	340,954		$	165,767
Restricted cash and cash equivalents		4,664			881			840
Total cash, cash equivalents and restricted cash	$	609,451		$	341,835		$	166,607

Tempus AI, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, except per share amounts)

	Year Ended December 31,
	2025		2024		2023
Supplemental disclosure of cash flow information
Cash paid during the year for interest	$	44,031	$	28,045	$	16,913
Cash paid for income taxes	$	654	$	206	$	161
Marketable equity securities received on accounts receivable	$	32,000	$	22,000	$	22,000

Supplemental disclosure of noncash investing and financing activities
Dividends payable	$	—	$	5,487	$	12,535
Purchases of property and equipment, accrued but not paid	$	5,535	$	4,292	$	6,137
Redemption of convertible promissory note	$	32,008	$	24,932	$	27,970
Non-voting common stock issued in connection with business combinations	$	—	$	344	$	9,209
Accretion of convertible preferred stock to redemption value	$	—	$	—	$	4,338
Deferred offering costs, accrued but not yet paid	$	47	$	—	$	3,504
Deferred financing fees, accrued but not yet paid	$	226	$	—	$	—
Reclassification of deferred offering costs to additional paid-in capital upon at-the-market offering	$	821	$	—	$	—
Operating lease liabilities arising from obtaining right-of-use assets	$	22,670	$	1,997	$	1,097
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering	$	—	$	1,348,809	$	—
Taxes related to net share settlement of restricted stock units not yet paid	$	—	$	20	$	—
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering	$	—	$	12,347	$	—
Class A Common Stock issued in connection with business combinations	$	403,154	$	—	$	—
Class A Common Stock issued in connection with license agreement	$	1,443	$	—	$	—
Issuance of Series G-3 Preferred Stock	$	—	$	3,809	$	2,738
Issuance of Series G-4 Preferred Stock	$	—	$	611	$	—
Issuance of warrant	$	—	$	—	$	4,223
Issuance of common stock in connection with contingent consideration	$	—	$	847	$	—
Convertible promissory note principal reset due to amendment	$	72,488	$	—	$	—

Tempus AI, Inc. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (Unaudited) (in thousands, except percentages and per share amounts) *Diagnostics Gross Profit & Gross Margin*

	Three Months Ended December 31,						Year Ended December 31,
	2025			2024			2025			2024
Diagnostics revenue	$	266,856		$	120,434		$	955,381		$	451,749
Cost of revenues, diagnostics		102,920			62,182			386,102			243,467
Gross profit, diagnostics	$	163,936		$	58,252		$	569,279		$	208,282
Stock-based compensation expense		2,138			1,215			6,224			13,625
Employer payroll tax related to stock-based compensation		35			293			373			455
Non-GAAP gross profit, diagnostics	$	166,109		$	59,760		$	575,876		$	222,362
Diagnostics gross margin		61.4	%		48.4	%		59.6	%		46.1	%
Stock-based compensation expense		0.8	%		1.0	%		0.7	%		3.0	%
Employer payroll tax related to stock-based compensation		0.0	%		0.2	%		0.0	%		0.1	%
Non-GAAP gross margin, diagnostics		62.2	%		49.6	%		60.3	%		49.2	%

*Data and applications Gross Profit & Gross Margin*

	Three Months Ended December 31,						Year Ended December 31,
	2025			2024			2025			2024
Data and applications revenue	$	100,355		$	80,246		$	316,408		$	241,649
Cost of revenues, data and applications		26,578			16,434			87,790			68,818
Gross profit, data and applications	$	73,777		$	63,812		$	228,618		$	172,831
Stock-based compensation expense		893			385			3,091			8,530
Employer payroll tax related to stock-based compensation		48			202			268			364
Non-GAAP gross profit, data and applications	$	74,718		$	64,399		$	231,977		$	181,725
Gross margin, data and applications		73.5	%		79.5	%		72.3	%		71.5	%
Stock-based compensation expense		0.9	%		0.5	%		1.0	%		3.5	%
Employer payroll tax related to stock-based compensation		0.0	%		0.3	%		0.1	%		0.2	%
Non-GAAP gross margin, data and applications		74.5	%		80.3	%		73.3	%		75.2	%

*Total Gross Profit & Gross Margin*

	Three Months Ended December 31,						Year Ended December 31,
	2025			2024			2025			2024
Net revenue	$	367,211		$	200,680		$	1,271,789		$	693,398
Cost of revenues		129,498			78,616			473,892			312,285
Gross profit	$	237,713		$	122,064		$	797,897		$	381,113
Stock-based compensation expense		3,031			1,600			9,315			22,155
Employer payroll tax related to stock-based compensation		83			495			641			819
Non-GAAP gross profit	$	240,827		$	124,159		$	807,853		$	404,087
Gross margin		64.7	%		60.8	%		62.7	%		55.0	%
Stock-based compensation expense		0.8	%		0.8	%		0.7	%		3.2	%
Employer payroll tax related to stock-based compensation		0.0	%		0.2	%		0.1	%		0.1	%
Non-GAAP gross margin		65.6	%		61.9	%		63.5	%		58.3	%

*Operating Expenses*

	Three Months Ended December 31,				Year Ended December 31,
	2025		2024		2025		2024
Technology research and development	$	40,147	$	31,864	$	146,107	$	167,519
Stock-based compensation expense		6,995		4,110		19,062		58,473
Employer payroll tax related to stock-based compensation		186		1,306		1,220		2,747
Non-GAAP technology research and development	$	32,966	$	26,448	$	125,825	$	106,299
Research and development	$	50,471	$	29,612	$	172,924	$	149,325
Stock-based compensation expense		5,070		2,851		12,688		47,638
Employer payroll tax related to stock-based compensation		99		756		632		1,566
Non-GAAP research and development	$	45,302	$	26,005	$	159,604	$	100,121
Selling, general and administrative	$	208,508	$	111,288	$	731,738	$	755,351
Stock-based compensation expense		30,243		16,226		83,682		405,872
Employer payroll tax related to stock-based compensation		3,006		5,023		9,046		8,411
Acquisition related expenses⁽¹⁾		143		2,708		6,216		2,708
Amortization of intangibles due to acquisition		16,838		—		61,529		—
Franchise taxes related to IPO		—		—		1,647		—
Non-GAAP selling, general and administrative	$	158,278	$	87,331	$	569,618	$	338,360
Operating expenses	$	299,126	$	172,764	$	1,050,769	$	1,072,195
Stock-based compensation expense		42,308		23,187		115,432		511,983
Employer payroll tax related to stock-based compensation		3,291		7,085		10,898		12,724
Acquisition related expenses⁽¹⁾		143		2,708		6,216		2,708
Amortization of intangibles due to acquisition		16,838		—		61,529		—
Franchise taxes related to IPO		—		—		1,647		—
Non-GAAP operating expenses	$	236,546	$	139,784	$	855,047	$	544,780

⁽¹⁾	Acquisition related expenses consist of legal, diligence, accounting, and financing costs, incurred for acquisitions during the three months and years ended December 31, 2025 and 2024.

*Earnings per Share*

	Three Months Ended December 31,						Year Ended December 31,
	2025			2024			2025			2024
Net loss	$	(54,166	)	$	(13,014	)	$	(245,028	)	$	(705,809	)
Fair value changes⁽¹⁾		(13,366	)		(47,753	)		(17,807	)		(27,868	)
Stock-based compensation expense		45,339			24,787			124,747			534,138
Employer payroll tax related to stock-based compensation		3,374			7,580			11,539			13,543
Acquisition related expenses⁽²⁾		(136	)		2,708			5,937			2,708
Amortization of intangibles due to acquisition		16,838			—			61,529			—
Losses from equity method investments		3,149			2,536			5,614			4,228
(Benefit from) provision for income taxes		(5,992	)		122			(51,684	)		266
G-4 Special Payment		—			—			—			2,250
Franchise taxes related to IPO		—			—			1,647			—
Other tax expense		1,608			—			1,608			—
Loss on debt extinguishment		—			—			12,034			—
Amortization of technology license		(3,989	)		(3,988	)		(15,955	)		(7,977	)
Non-GAAP net loss	$	(7,341	)	$	(27,022	)	$	(105,819	)	$	(184,521	)
Non-GAAP net loss per share	$	(0.04	)	$	(0.16	)	$	(0.61	)	$	(1.54	)
Weighted average common shares outstanding, basic and diluted		178,093			166,398			174,264			119,849

⁽¹⁾	Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities.
⁽²⁾	Acquisition related expenses consist of legal, diligence, accounting, and financing costs, as well as a gain on bargain purchase, incurred for acquisitions during the three months and years ended December 31, 2025 and 2024.

*Adjusted EBITDA*

	Three Months Ended December 31,						Year Ended December 31,
	2025			2024			2025			2024
Net loss	$	(54,166	)	$	(13,014	)	$	(245,028	)	$	(705,809	)
Interest income		(5,122	)		(3,546	)		(12,628	)		(11,084	)
Interest expense		15,286			13,359			70,267			53,653
Depreciation		7,704			6,884			32,054			26,356
Amortization		19,204			2,573			70,270			10,889
(Benefit from) provision for income taxes		(5,992	)		122			(51,684	)		266
EBITDA	$	(23,086	)	$	6,378		$	(136,749	)	$	(625,729	)
Losses from equity method investments		3,149			2,536			5,614			4,228
Fair value changes⁽¹⁾		(13,366	)		(47,753	)		(17,807	)		(27,868	)
Stock-based compensation expense		45,339			24,787			124,747			534,138
Employer payroll tax related to stock-based compensation		3,374			7,580			11,539			13,543
Acquisition related expenses⁽²⁾		(136	)		2,708			5,937			2,708
G-4 Special Payment		—			—			—			2,250
Amortization of technology license		(3,989	)		(3,988	)		(15,955	)		(7,977	)
Franchise taxes related to IPO		—			—			1,647			—
Other tax expense		1,608			—			1,608			—
Loss on debt extinguishment		—			—			12,034			—
Adjusted EBITDA	$	12,893		$	(7,752	)	$	(7,385	)	$	(104,707	)

⁽¹⁾	Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities.
⁽²⁾	Acquisition related expenses consist of legal, diligence, accounting, and financing costs, as well as a gain on bargain purchase, incurred for acquisitions of during the three months and years ended December 31, 2025 and 2024.

	Three Months Ended September 30,
	2025
Net loss	$	(79,982	)
Interest income		(4,600	)
Interest expense		15,399
Depreciation		8,120
Amortization		18,911
Provision for income taxes		276
EBITDA	$	(41,876	)
Gains on equity method investments		(1,518	)
Fair value changes⁽¹⁾		1,255
Stock-based compensation expense		33,979
Employer payroll tax related to stock-based compensation		1,039
Acquisition related expenses⁽²⁾		552
Amortization of technology license		(3,989	)
Loss on debt extinguishment		12,034
Adjusted EBITDA	$	1,476

⁽¹⁾	Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities.
⁽²⁾	Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions of during the three months ended September 30, 2025.

*Loss from Operations*

	Three Months Ended December 31,						Year Ended December 31,
	2025			2024			2025			2024
Loss from operations	$	(61,413	)	$	(50,700	)	$	(252,872	)	$	(691,082	)
Stock-based compensation expense		45,339			24,787			124,747			534,138
Employer payroll tax related to stock-based compensation		3,374			7,580			11,539			13,543
Acquisition related expenses⁽¹⁾		143			2,708			6,216			2,708
Franchise taxes related to IPO		—			—			1,647			—
Amortization of intangibles due to acquisition		16,838			—			61,529			—
Non-GAAP loss from operations	$	4,281		$	(15,625	)	$	(47,194	)	$	(140,693	)

⁽¹⁾	Acquisition related expenses consist of legal, diligence, accounting, and financing costs, incurred for acquisitions during the three months and years ended December 31, 2025 and 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224126737/en/

Tempus Communications

Hanah Heintzelman

[email protected]

Tempus Investor Relations

Elizabeth Krutoholow

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Technology Health Technology Telemedicine/Virtual Medicine Software Biotechnology General Health Pharmaceutical Health Data Management Artificial Intelligence

MEDIA:

Logo

February 24, 2026 4:05 pm

NetApp to Participate in Upcoming Conferences

NetApp to Participate in Upcoming Conferences

SAN JOSE, Calif.–(BUSINESS WIRE)–
NetApp^TM (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced the Company will participate in fireside chats at the following conferences:

Raymond James Institutional Investor Conference

Presenter: Kris Newton, VP, Investor Relations

Date: March 3, 2026

Presentation Time: 1:40 – 2:10 p.m. Eastern Time

Morgan Stanley TMT Conference

Presenter: George Kurian, CEO

Date: March 4, 2026

Presentation time: 7:45 – 8:20 a.m. Pacific Time

Live audio Webcasts of the presentations will be available at investors.netapp.com. Audio Webcast archives of each event will be available after the conferences.

About NetApp

For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.

At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.

Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.

With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224724127/en/

(Press)

Kenya Hayes

1 703 589 7595

[email protected]

(Investors)

Billie Fagenstrom

1 408 822 6428

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Internet Security Data Management Technology Software

MEDIA:

Logo

February 24, 2026 4:05 pm

RF Acquisition Corp III Announces the Separate Trading of its Ordinary Shares and Rights Commencing February 26, 2026

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) — RF Acquisition Corp III (the “Company” or “we”) announced that, commencing February 26, 2026, holders of the 10,000,000 units sold in the Company’s initial public offering may elect to separately trade the ordinary shares and rights included in the units. Any units not separated will continue to trade on the Global Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “RFAMU,” and the separated ordinary shares and rights are expected to trade on Nasdaq under the symbols “RFAM” and “RFAMR,” respectively.

Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into ordinary shares and rights.

The units were initially offered by the Company in an underwritten offering. EarlyBirdCapital, Inc. acted as sole book-running manager of the offering. The registration statement relating to the units and the underlying securities became effective on January 30, 2026.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About RF Acquisition Corp III

RF Acquisition Corp III is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While we will not be limited to a particular industry or geographic region in our identification and acquisition of a target company, we intend to focus our search on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology. However, we will not undertake our initial business combination with any company based in or having the majority of its operations in Greater China.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated separation of the units into ordinary shares and rights. No assurance can be given that the units will be separated as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and final prospectus relating to the Company’s initial public offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:

Tse Meng Ng
Chairman and CEO
[email protected]

February 24, 2026 4:04 pm

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively

2026 U.S. net product revenue projected at $225 – $250 million

Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC)

Day One to host conference call and webcast today, February 24, 4:30 p.m. ET

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its financial results for the fourth quarter and full year 2025, and reaffirms its outlook for 2026.

“2025 was a seminal year for Day One, marked by significant achievements across every pillar of our organization. By maintaining our strong commercial execution, leveraging our expertise to extend into additional rare cancers, and steadily advancing our early-stage pipeline, we are delivering on our mission to bring new medicines to people of all ages with life-threatening diseases,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “The commercial momentum we’ve established for OJEMDA and the important upcoming clinical data updates across our full pipeline position us for strong growth in 2026 and beyond.”

OJEMDA Commercial Performance

OJEMDA net product revenue of $52.8 million and $155.4 million for the fourth quarter and full year 2025, respectively
Full-year 2025 net product revenue represented 172% year-over-year growth, with double-digit sequential quarterly growth throughout the year
Fourth quarter prescription volumes increased to 1,394 and total 2025 prescriptions were 4,635, representing 181% growth versus 2024 (April launch), and demonstrating strong and growing patient demand, increasing treatment persistence and expanding prescriber adoption
Company reaffirmed its previously announced 2026 U.S. OJEMDA net product revenue guidance of $225 million to $250 million

Clinical and Pipeline Highlights

FIREFLY-1 Progress in 2025 and Frontline pLGG FIREFLY-2 Trial Enrollment Complete in 2026

Updated three-year data from the pivotal Phase 2 FIREFLY-1 trial presented at the Society for Neuro-Oncology Annual Meeting in November 2025, reinforcing the durability of response and long-term safety profile of OJEMDA in patients with relapsed or refractory pLGG
Long term follow-up data from FIREFLY-1 demonstrate that time to next treatment analyses better reflected clinical decision-making among FIREFLY-1 investigators versus radiographic-only tumor progression (as assessed via traditional progression free survival analyses)
Enrollment in the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in patients with frontline pLGG remains on track, with full enrollment anticipated in the first half of 2026

Pipeline Progress in 2026

Updated Phase 1 clinical data on Emi-Le, a B7-H4-directed ADC acquired from Mersana, expected to be available mid-2026
The Phase 1a clinical trial of DAY301, a PTK7-targeted ADC, is progressing through dose escalation, with initial clinical data and program update planned for the second half of 2026

2025 Financial Summary

Net Product Revenue: OJEMDA net product revenues were $52.8 million and $155.4 million for the fourth quarter and full year 2025, respectively
License Revenue: License revenues from the sale of ex-U.S. commercial rights for tovorafenib were $0.9 million and $2.8 million for the fourth quarter and full year 2025, respectively
R&D Expenses: Research and development expenses were $40.9 million and $148.1 million for the fourth quarter and full year 2025, respectively, as compared to $61.8 million and $227.7 million for the same periods in 2024
SG&A Expenses: Selling, general and administrative expenses were $34.2 million and $120.6 million for the fourth quarter and full year 2025, respectively, as compared to $29.8 million and $115.5 million for the same periods in 2024
Net Loss: Net loss totaled $21.3 million and $107.3 million for the fourth quarter and full year 2025, respectively, with non-cash stock-based compensation expense of $11.1 million and $44.4 million for the same periods. By comparison, net loss totaled $65.7 million and $95.5 million for the fourth quarter and full year 2024, respectively, with non-cash stock-based compensation expense of $11.0 million and $48.3 million for the same periods
Cash Position: The Company’s cash, cash equivalents and short-term investments totaled $441.1 million as of December 31, 2025

Upcoming Events

46^th Annual TD Cowen Health Care Conference
- Management will participate in a fireside chat on Tuesday, March 3 at 9:10 a.m. Eastern Time. A live and archived audio webcast of the discussion will be available by visiting the Events section of the Company’s website
2026 Leerink Partners Global Healthcare Conference
- Management presentation on Wednesday, March 11 at 1:40 p.m. Eastern Time. A live and archived audio webcast of the discussion will be available by visiting the Events section of the Company’s website

Conference Call

Day One will host a conference call and webcast today, February 24 at 4:30 p.m. Eastern Time. To access the live conference call by phone, dial 877-704-4453 (domestic) or 201-389-0920 (international), and provide the access code 13745150. Live audio webcast will be accessible from the Day One Media & Investors page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301, and following the recently announced acquisition of Mersana Therapeutics, Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).

Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One’s ability to grow revenue from OJEMDA, plans to develop and commercialize cancer therapies and its pipeline and the impact of Emi-Le and DAY301, and statements regarding its net product revenues, cash, cash equivalents and short-term investments. Statements including words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that may cause Day One’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including risks related to the ability to realize the anticipated benefits of the Mersana acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of the consummation of the acquisition on the market price of Day One’s common stock and/or operating results; significant transaction costs; unknown liabilities, Day One’s ability to develop, obtain and retain regulatory approval for or commercialize any product candidate, Day One’s ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of inflation, government shutdowns, rising interest rates, instability in the global banking system, geopolitical conflicts and the sufficiency of Day One’s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Day One Biopharmaceuticals, Inc. Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited)

	Year Ended December 31,
		2025			2024			2023
Revenue:
Product revenue, net	$	155,421		$	57,217		$	—
License revenue		2,761			73,944			—
Total revenues		158,182			131,161			—
Cost and operating expenses:
Cost of product revenue		14,714			4,763			—
Cost of license revenue		2,496			516			—
Research and development		148,135			227,702			130,521
Selling, general and administrative		120,587			115,450			75,543
Total cost and operating expenses		285,932			348,431			206,064
Loss from operations		(127,750	)		(217,270	)		(206,064	)
Non-operating income:
Gain from sale of priority review voucher		—			108,000			—
Investment income, net		18,471			19,701			17,187
Other (expense) income, net		(19	)		1,217			(40	)
Total non-operating income, net		18,452			128,918			17,147
Loss before income taxes		(109,298	)		(88,352	)		(188,917	)
Income tax benefit (expense)		1,976			(7,144	)		—
Net loss		(107,322	)		(95,496	)		(188,917	)
Net loss per share – basic	$	(1.04	)	$	(1.02	)	$	(2.37	)
Net loss per share – diluted	$	(1.04	)	$	(1.02	)	$	(2.37	)
Weighted-average number of common shares used in net loss per share – basic		103,205,703			93,234,195			79,773,004
Weighted-average number of common shares used in net loss per share – diluted		103,205,703			93,234,195			79,773,004

Day One Biopharmaceuticals, Inc. Selected Consolidated Balance Sheet Data (in thousands) (unaudited)

	December 31, 2025			December 31, 2024
Cash, cash equivalents and short-term investments	$	441,113		$	531,720
Total assets		507,827			582,788
Total liabilities		66,665			80,037
Accumulated deficit		(661,403	)		(554,081	)
Total stockholders’ equity		441,162			502,751

DAY ONE MEDIA

[email protected]

DAY ONE INVESTORS

LifeSci Advisors, PJ Kelleher
[email protected]

February 24, 2026 4:04 pm

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe;

U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability

Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026

Expect to Share Topline Results from ACACIA-HCM in Q2 2026

Company Provides 2026 Financial Guidance;

~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance.

“The fourth quarter of 2025 marked a defining moment for Cytokinetics with the FDA approval of MYQORZO and our transition into a commercial-stage company,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “With the U.S. launch of MYQORZO now underway and our first European launch planned in Germany in Q2, we’re entering 2026 with strong momentum. Early prescribing activity and initial customer feedback reinforce that our differentiated label and REMS are resonating with HCPs and patients. We took measures in 2025 to fortify our balance sheet to support our commercial plans and continue with potential label-expanding opportunities in HCM and ongoing clinical trials in heart failure. We are well-positioned to deliver for patients, advance our pipeline, and create long-term value.”

Q4 and Recent Highlights

Cardiac Muscle Programs

MYQORZO™
(

aficamten

) (cardiac myosin inhibitor)

Received approval in December from the U.S. Food and Drug Administration (FDA) for MYQORZO (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Began U.S. commercial launch of MYQORZO in January:
- Deployed Cardiovascular Account Specialists, who began promotion to healthcare providers (HCPs) in early January.
- Launched patient and HCP marketing campaigns across promotional channels.
- Activated online portal for MYQORZO REMS simultaneous with drug availability.
- Launched MYQORZO & You™ to provide personalized patient support, access and reimbursement assistance and affordability programs for eligible patients.
Announced approval from the China National Medical Products Administration (NMPA) for MYQORZO for the treatment of adults with New York Heart Association (NYHA) class II-III oHCM, to improve exercise capacity and symptoms.
Received approval from the European Commission (EC) for MYQORZO for the treatment of symptomatic (NYHA class II-III) oHCM in adult patients, following the adoption of a positive opinion recommending marketing authorization in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Advanced European commercial readiness activities, including preparing Health Technology Assessment (HTA) dossiers for all key European markets. Expanded launch readiness activities and continued hiring of medical and commercial teams in Germany ahead of expected Q2 2026 launch.
The New Drug Submission (NDS) for aficamten was accepted for review by Health Canada.
Submitted Supplemental New Drug Application (sNDA) to the FDA for MAPLE-HCM.
Advanced the ongoing clinical trials program for aficamten:
- Continued conduct of ACACIA-HCM, a pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). Continued conduct in the Japan cohort of ACACIA-HCM.
- Completed enrollment of CAMELLIA-HCM, a Phase 3 clinical trial of aficamten in Japanese patients with oHCM. CAMELLIA-HCM is being conducted by Bayer in collaboration with Cytokinetics to support potential marketing authorization in Japan.
- Continued enrolling patients in CEDAR-HCM, a clinical trial of aficamten in a pediatric population with symptomatic oHCM.

Presented additional data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 expanding on the treatment effect of aficamten vs. metoprolol on patient symptom burden and cardiac biomarkers and showing that significantly more patients on aficamten achieved positive or complete response compared to metoprolol.
Published the following manuscripts:
- “Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023” in Journal of the American College of Cardiology: Advances.
- “Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial” in Journal of the American College of Cardiology.
- “Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy” in Journal of the American College of Cardiology.
- “Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM” in Circulation: Heart Failure.
- “Efficacy and Safety of Aficamten in Children and Adolescents with Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM” in Circulation: Heart Failure.
- “Efficacy and Safety of Extended Treatment with Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy in FOREST-HCM” in European Heart Journal.
- “Longitudinal Analyses of Healthcare Resource Utilization and Costs Among Patients with Obstructive Hypertrophic Cardiomyopathy” in Journal of Medical Economics.
- “Impact of Cardiovascular Complications on Economic Burden for Patients with Hypertrophic Cardiomyopathy” in Journal of Cardiac Failure – Intersections.

omecamtiv mecarbil
(cardiac myosin activator)

Continued conduct of COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
Published the following manuscripts:
- “Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Age: the GALACTIC-HF Trial” in Journal of the American College of Cardiology – Heart Failure.
- “Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects” in Drugs in R&D.

ulacamten
(cardiac myosin inhibitor)

Continued patient enrollment in Cohort 1 of AMBER-HFpEF, a Phase 2 clinical trial of ulacamten in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥ 60%.

Pre-Clinical Development and Ongoing Research

Continued pre-clinical development and research activities directed to additional muscle biology focused programs.

Corporate

Supported a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with HCM.

Expected 2026 Corporate Milestones

Cardiac Muscle Programs

MYQORZO® (

aficamten

)
(cardiac myosin inhibitor)

Report topline results from ACACIA-HCM in Q2 2026.
Launch MYQORZO in Germany in Q2 2026.
Receive potential FDA approval of the sNDA for MAPLE-HCM in Q4 2026.
Complete enrollment in the adolescent cohort of CEDAR-HCM in Q4 2026.
Receive potential approval from Health Canada in 2H 2026.

omecamtiv mecarbil

(cardiac myosin activator)

Continue patient enrollment in COMET-HF through 2026.

ulacamten

(cardiac myosin inhibitor)

Complete enrollment in Cohort 1 of AMBER-HFpEF in Q1 2026, and complete enrollment in Cohort 2 by the end of 2026.

Ongoing research

Continue ongoing pre-clinical development and research activities directed to additional muscle biology focused programs

Fourth Quarter and Full Year 2025 Financial Results

Cash Equivalents and Investments

As of December 31, 2025, the company had approximately $1.22 billion in cash, cash equivalents and investments compared to $1.25 billion at September 30, 2025. The 2025 year-end balance includes $100 million in proceeds from the drawing on the Tranche 5 of the Royalty Pharma Multi Tranche Loan. Excluding the proceeds from this loan, cash, cash equivalents and investments would have declined by approximately $134 million during the fourth quarter of 2025.

Revenues

Total revenues for the fourth quarter of 2025 were $17.8 million compared to $16.9 million for the same period in 2024. Total revenues for the full year of 2025 were $88.0 million compared to $18.5 million in 2024. Total revenues for the full year 2025 benefitted primarily from the successful completion of the technology transfer totaling $52.4 million to Bayer Consumer Care AG, an affiliate of Bayer AG, in the second quarter of 2025 and the recognition of $15.0 million in the fourth quarter of 2025 related to milestones triggered by the approvals of MYQORZO in the United States and China under the Sanofi License Agreement.

Research and Development (R&D) Expenses

R&D expenses for the fourth quarter of 2025 were $104.4 million, which included $14.2 million of non-cash stock-based compensation expense, compared to $93.6 million for the same period in 2024, which included $12.5 million of non-cash stock-based compensation expense. R&D expenses for the full year of 2025 were $416.0 million, which included $54.5 million of non-cash stock-based compensation compared to $339.4 million in 2024, which included $44.0 million of non-cash stock-based compensation expense. The increase for the full year was primarily due to advancing our clinical trials, higher personnel-related costs including stock-based compensation, and medical affairs activities.

General and Administrative (G&A) Expenses

G&A expenses for the fourth quarter of 2025 were $91.7 million, which included $16.3 million of non-cash stock-based compensation expense, compared to $62.3 million for the same period in 2024, which included $13.8 million of non-cash stock-based compensation expense. G&A expenses for the full year of 2025 were $284.3 million, which included $57.7 million of non-cash stock-based compensation compared to $215.3 million in 2024, which included $53.8 million of non-cash stock-based compensation expense. The increase for the full year was primarily driven by investments toward commercial readiness including the hiring of our U.S. sales force primarily in the fourth quarter of 2025 and higher non-sales personnel-related costs.

Net Income (Loss)

Net loss for the fourth quarter of 2025 was $183.0 million, or $(1.50) per share, basic and diluted, compared to a net loss of $150.0 million, or $(1.26) per share, basic and diluted, for the same period in 2024. Net loss for the year of 2025 was $785.0 million, or $(6.54) per share, basic and diluted, compared to a net loss of $589.5 million, or $(5.26) per share, basic and diluted, in 2024.

2026 Financial Guidance

The company today announced financial guidance for 2026:

GAAP Combined R&D and SG&A Expense*	$830 million to $870 million
Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A Expense	$130 million to $120 million

*GAAP Combined R&D and SG&A expense does not include 1) collaboration expenses which can include reimbursed expenses and cost of inventory sales of aficamten to partners, 2) potential costs related to commercialization of aficamten in nHCM, and 3) the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities.

Conference Call and Webcast Information

Members of Cytokinetics’ senior management team will review the company’s fourth quarter 2025 results on a conference call today at 4:30 PM Eastern Time. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics’ website for six months.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but not limited to, statements, express or implied, relating to our ability to launch MYQORZO in Germany in 2Q of 2026, our receipt of regulatory approval for our sNDA for MAPLE-HCM in Q4 of 2026, our or our partners’ research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of any of our clinical trials, or more specifically, our ability to complete enrollment of CEDAR-HCM and AMBER-HFpEF by any target date, our ability to complete patient enrollment of COMET-HF by any target date, our ability to announce the results of ACACIA-HCM in of the second quarter of 2026, our ability to announce the results of any of our clinical trials by any particular date, the timing of interactions with FDA or any other regulatory authorities in connection to any of our drug candidates and the outcomes of such interactions; statements relating to the potential patient population who could benefit from aficamten, omecamtiv mecarbil, ulacamten, CK-089 or any of our other drug candidates; statements relating to our ability to receive additional capital or other funding, including, but not limited to, our ability to meet any of the conditions relating to or to otherwise secure additional loan disbursements under any of our agreements with entities affiliated with Royalty Pharma or additional milestone payments from Sanofi or Bayer in connection with our collaborations for aficamten in China or Japan respectively; statements relating to our operating expenses or cash utilization for the remainder of 2025 or any other period, and statements relating to our cash balance at any particular date or the amount of cash runway such cash balances represent at any particular time. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Cytokinetics’ need for additional funding and such additional funding may not be available on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; Cytokinetics may incur unanticipated research and development and other costs; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission, particularly under the caption “Risk Factors” in Cytokinetics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^TM is a trademark of Cytokinetics in the U.S., and a registered trademark in the European Union.

MYQORZO & You^TM is a trademark of Cytokinetics in the U.S.

Contact:

Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757


Cytokinetics, Incorporated
Condensed Consolidated Balance Sheets
(in thousands)


	December 31, 2025			December 31, 2024
	(unaudited)
ASSETS
Current assets:
Cash and short-term investments	$	882,221		$	1,076,014
Other current assets		34,754			31,926
Total current assets		916,975			1,107,940
Long-term investments		335,048			145,055
Property and equipment, net		79,194			65,815
Operating lease right-of-use assets		75,979			75,158
Other assets		17,341			7,705
Total assets	$	1,424,537		$	1,401,673
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued liabilities	$	105,615		$	75,692
Short-term operating lease liabilities		19,111			18,978
Current portion of convertible and long-term debt		41,181			11,520
Derivative liabilities measured at fair value		31,100			11,300
Deferred revenue		1,612			52,370
Other current liabilities		3,833			9,814
Total current liabilities		202,452			179,674
Term loan, net		246,384			93,227
Convertible notes, net		869,597			552,370
Liabilities related to revenue participation right purchase agreements, net		520,559			462,192
Long-term operating lease liabilities		107,970			112,582
Liabilities related to RPI Transactions measured at fair value		137,200			137,000
Total liabilities		2,084,162			1,537,045
Commitments and contingencies
Stockholders’ deficit
Common stock		123			118
Additional paid-in capital		2,826,341			2,563,876
Accumulated other comprehensive income		630			2,398
Accumulated deficit		(3,486,719	)		(2,701,764	)
Total stockholders’ deficit		(659,625	)		(135,372	)
Total liabilities and stockholders’ deficit	$	1,424,537		$	1,401,673

Cytokinetics, Incorporated
Condensed Consolidated Statements of Operations
(in thousands except per share data)
(unaudited)

	Three Months Ended December 31,						Years Ended December 31,
	2025			2024			2025			2024
Revenues:
Collaboration revenues	$	2,755		$	1,927		$	8,686		$	3,474
License and milestone revenues		15,000			15,000			79,353			15,000
Total revenues		17,755			16,927			88,039			18,474
Operating expenses:
Research and development		104,398			93,629			416,026			339,408
General and administrative		91,723			62,338			284,271			215,314
Total operating expenses		196,121			155,967			700,297			554,722
Operating loss		(178,366	)		(139,040	)		(612,258	)		(536,248	)
Interest expense		(14,274	)		(8,938	)		(45,579	)		(37,701	)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements		(16,061	)		(13,656	)		(58,289	)		(48,811	)
Interest and other income, net		11,470			15,014			48,420			51,534
Change in fair value of derivative liabilities		900			1,200			4,200			1,300
Change in fair value of liabilities related to RPI Transactions		13,300			(4,600	)		(200	)		(19,600	)
Debt conversion expense		—			—			(121,249	)		—
Net loss	$	(183,031	)	$	(150,020	)	$	(784,955	)	$	(589,526	)
Net loss per share — basic and diluted	$	(1.50	)	$	(1.26	)	$	(6.54	)	$	(5.26	)
Weighted-average shares in net loss per share — basic and diluted		122,434			118,075			120,103			111,979

February 24, 2026 4:03 pm

Accelerant Announces Leadership Updates Across Legal and Investor Relations

Accelerant Announces Leadership Updates Across Legal and Investor Relations

Cliff Jenks Named General Counsel and Corporate Secretary; Ray Iardella Will Join Company as Head of Investor Relations Beginning in Early March

ATLANTA–(BUSINESS WIRE)–Accelerant(NYSE: ARX), a data-driven company modernizing specialty insurance through the Accelerant Risk Exchange, today announced the appointments of Cliff Jenks as General Counsel and Corporate Secretary and Ray Iardella as Head of Investor Relations. Jenks will oversee Accelerant’s legal affairs and corporate governance, while Iardella will lead the company’s engagement with the investment community.

Cliff Jenks joins Accelerant with more than 20 years of experience in capital markets transactions, third party capital, M&A, investment transactions, and public company governance. Most recently, he served as Senior Vice President, Corporate and Securities Counsel and Corporate Secretary at Reinsurance Group of America (NYSE: RGA), where he held leadership roles for more than 14 years. Earlier in his career, Jenks advised public companies on complex transactions, disclosure, and compliance matters.

Jenks will succeed Nancy Hasley, who is retiring following a distinguished tenure with the company beginning in its earliest days in 2019 through its initial public offering. The leadership transition will be effective March 31, 2026.

“I am honored to join Accelerant and build on the strong foundation and experienced legal team already in place,” said Jenks. “The Accelerant Risk Exchange represents a differentiated model within specialty insurance, and I look forward to supporting Accelerant’s continued growth through strategic legal guidance and a commitment to the highest standards of corporate governance.”

In the newly created role of Head of Investor Relations, Ray Iardella will direct the company’s strategic communications with institutional investors and analysts.

With more than two decades of financial markets and insurance industry experience, Iardella recently served as Vice President of Investor Relations at Arthur J. Gallagher & Co. (NYSE: AJG), where he helped shape the company’s strategic positioning with the investment community. Prior to Gallagher, he held senior analyst and actuarial roles with leading insurance, financial, and asset management firms.

“I’m thrilled to join Accelerant at this pivotal stage of growth,” said Iardella. “As AI reshapes the global economy, companies that combine deep data insight with scalable platforms will drive superior value creation. Within specialty insurance the Accelerant Risk Exchange is leading the charge, and I am excited to articulate that compelling strategy to the investment community.”

“Cliff and Ray bring deep expertise that will support Accelerant as we continue to scale the Accelerant Risk Exchange,” said Jeff Radke, Accelerant CEO. “Cliff’s extensive background in corporate governance and securities law will ensure we continue to operate with rigor and discipline as a public company, while Ray’s investor relations expertise and nuanced understanding of the insurance industry will be invaluable in strengthening clarity, consistency, and confidence for our investors.”

About Accelerant

Accelerant operates the Accelerant Risk Exchange, a data-driven platform that connects specialty insurance underwriters with risk capital providers through advanced analytics, real-time data, and transparent underwriting insights. The platform supports diversified, low-volatility premium performance and scalable capital deployment across cycles. For more information, visit investor.accelerant.ai or inquire via email at [email protected].

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224638727/en/

Chelsea Allison, COMMAND for Accelerant

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Legal Software Insurance Finance Public Relations/Investor Relations Communications Professional Services Technology

MEDIA:

Logo

Posted on February 24, 2026 4:03 pm
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

Alkermes to Present at the TD Cowen 46^th Annual Health Care Conference

DUBLIN–(BUSINESS WIRE)–Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46^th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224148567/en/

Alkermes Contact:

Jamie Constantine

Investor Relations

+1 781 873 2402

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Biotechnology General Health Mental Health Health Pharmaceutical

MEDIA:

Logo

Posted on February 24, 2026 4:03 pm
Expedia Group to Participate in Morgan Stanley’s 2026 TMT Conference

Expedia Group to Participate in Morgan Stanley’s 2026 TMT Conference

SEATTLE–(BUSINESS WIRE)–
Expedia Group (NASDAQ: EXPE) will participate in Morgan Stanley’s 2026 Technology, Media & Telecom Conference. Scott Schenkel, Chief Financial Officer, will participate in a fireside chat on Tuesday, March 3, 2026 at 10:00 am PT / 1:00 pm ET.

A live webcast of the session will be available at http://ir.expediagroup.com. A replay of the webcast will be accessible for 3 months.

About Expedia Group

Expedia Group, Inc. (NASDAQ: EXPE) is the global travel marketplace with one purpose: to help travelers explore the world, one journey at a time. Expedia Group™ connects travelers, partners, and advertisers through its trusted brands, leading technology, and rich first-party data, delivering predictive, personalized experiences that shape the future of travel.

Expedia Group’s ecosystem includes three flagship consumer brands – Expedia®, Hotels.com®, and Vrbo® – the largest B2B travel business, and a premier advertising network. Guided by an experienced and passionate global team, Expedia Group helps millions of travelers in more than 70 countries explore the world with confidence and ease.

© 2026 Expedia, Inc., an Expedia Group company. All rights reserved. Expedia Group and the Expedia Group logo are trademarks of Expedia, Inc. CST: 2029030-50.

For more information, visit www.expediagroup.com. Follow Expedia Group on Facebook, Instagram, X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224420772/en/

Investor Relations

[email protected]

Communications

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Technology Electronic Commerce Other Travel Internet Lodging Retail Destinations Travel Online Retail

MEDIA:

Logo

Posts pagination

Page 1 Page 2 … Page 41,033 Next page